News and Trends 25 Aug 2014
KalVista start the clinical development of a new treatment for diabetic macular edema
KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study’s principal investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin Diabetes Center. […]